-
Something wrong with this record ?
Rational design of PLA-based ASDs for pharmaceutical 3D printing: Insights from phase diagram modeling
ALV. Zumaya, A. Iemtsev, M. Fulem, F. Hassouna
Language English Country Netherlands
Document type Journal Article
- MeSH
- Printing, Three-Dimensional * MeSH
- Citrates chemistry MeSH
- Calorimetry, Differential Scanning methods MeSH
- Chemistry, Pharmaceutical methods MeSH
- Technology, Pharmaceutical methods MeSH
- Indomethacin * chemistry MeSH
- Crystallization MeSH
- Naproxen chemistry MeSH
- Polyesters * chemistry MeSH
- Solvents chemistry MeSH
- Solubility * MeSH
- Drug Stability MeSH
- Thermodynamics MeSH
- Transition Temperature MeSH
- Triacetin chemistry MeSH
- Plasticizers * chemistry MeSH
- Publication type
- Journal Article MeSH
The integration of 3D printing into the pharmaceutical sciences opens new possibilities for personalized medicine. Poly(lactide) (PLA), a biodegradable and biocompatible polymer, is highly suitable for biomedical applications, particularly in the context of 3D printing. However, its processability often requires the addition of plasticizers. This study investigates the use of phase diagram modeling as a tool to guide the rational selection of plasticizers and to assess their impact on the thermodynamic and kinetic stability of PLA-based amorphous solid dispersions (ASDs) containing active pharmaceutical ingredients (APIs). Thermodynamic stability against API recrystallization was predicted based on the API solubility in PLA and Plasticizer-PLA carriers using the Conductor-like Screening Model for Real Solvents (COSMO-RS), while the kinetic stability of the ASDs was evaluated by modeling the glass transition temperatures of the mixtures. Two APIs, indomethacin (IND) and naproxen (NAP), with differing glass-forming abilities (i.e., recrystallization tendencies), and three plasticizers, triacetin (TA), triethyl citrate (TEC), and poly(L-lactide-co-caprolactone) (PLCL), were selected for investigation. The physical stability of ASD formulations containing 9 wt% API and plasticizer to PLA in two ratios, 10:81 and 20:71 w/w %, was monitored over time using differential scanning calorimetry and X-ray powder diffraction and compared with phase diagram predictions. All formulations were predicted to be thermodynamically unstable; however, those containing no plasticizer or with TEC and TA at 10 wt% were predicted to exhibit some degree of kinetic stability. Long-term physical studies corroborated these predictions. The correlation between the predicted phase behavior and long-term physical stability highlights the potential of phase diagram modeling as a tool for the rational design of ASDs in pharmaceutical 3D printing.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009645
- 003
- CZ-PrNML
- 005
- 20250429134611.0
- 007
- ta
- 008
- 250415e20250205ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2025.114657 $2 doi
- 035 __
- $a (PubMed)39921011
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Zumaya, Alma Lucia Villela $u Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 245 10
- $a Rational design of PLA-based ASDs for pharmaceutical 3D printing: Insights from phase diagram modeling / $c ALV. Zumaya, A. Iemtsev, M. Fulem, F. Hassouna
- 520 9_
- $a The integration of 3D printing into the pharmaceutical sciences opens new possibilities for personalized medicine. Poly(lactide) (PLA), a biodegradable and biocompatible polymer, is highly suitable for biomedical applications, particularly in the context of 3D printing. However, its processability often requires the addition of plasticizers. This study investigates the use of phase diagram modeling as a tool to guide the rational selection of plasticizers and to assess their impact on the thermodynamic and kinetic stability of PLA-based amorphous solid dispersions (ASDs) containing active pharmaceutical ingredients (APIs). Thermodynamic stability against API recrystallization was predicted based on the API solubility in PLA and Plasticizer-PLA carriers using the Conductor-like Screening Model for Real Solvents (COSMO-RS), while the kinetic stability of the ASDs was evaluated by modeling the glass transition temperatures of the mixtures. Two APIs, indomethacin (IND) and naproxen (NAP), with differing glass-forming abilities (i.e., recrystallization tendencies), and three plasticizers, triacetin (TA), triethyl citrate (TEC), and poly(L-lactide-co-caprolactone) (PLCL), were selected for investigation. The physical stability of ASD formulations containing 9 wt% API and plasticizer to PLA in two ratios, 10:81 and 20:71 w/w %, was monitored over time using differential scanning calorimetry and X-ray powder diffraction and compared with phase diagram predictions. All formulations were predicted to be thermodynamically unstable; however, those containing no plasticizer or with TEC and TA at 10 wt% were predicted to exhibit some degree of kinetic stability. Long-term physical studies corroborated these predictions. The correlation between the predicted phase behavior and long-term physical stability highlights the potential of phase diagram modeling as a tool for the rational design of ASDs in pharmaceutical 3D printing.
- 650 12
- $a 3D tisk $7 D066330
- 650 12
- $a polyestery $x chemie $7 D011091
- 650 12
- $a změkčovadla $x chemie $7 D010968
- 650 12
- $a indomethacin $x chemie $7 D007213
- 650 12
- $a rozpustnost $7 D012995
- 650 _2
- $a naproxen $x chemie $7 D009288
- 650 _2
- $a krystalizace $7 D003460
- 650 _2
- $a termodynamika $7 D013816
- 650 _2
- $a triacetin $x chemie $7 D014215
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a tranzitní teplota $7 D044366
- 650 _2
- $a citráty $x chemie $7 D002951
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a farmaceutická technologie $x metody $7 D013678
- 650 _2
- $a diferenciální skenovací kalorimetrie $x metody $7 D002152
- 650 _2
- $a rozpouštědla $x chemie $7 D012997
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Iemtsev, Anton $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Fulem, Michal $u Department of Physical Chemistry, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: fulemm@vscht.cz
- 700 1_
- $a Hassouna, Fatima $u Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: fatima.hassouna@vscht.cz
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics $x 1873-3441 $g Roč. 208 (20250205), s. 114657
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39921011 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134606 $b ABA008
- 999 __
- $a ok $b bmc $g 2311176 $s 1246726
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 208 $c - $d 114657 $e 20250205 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $a Pubmed-20250415